Abstract
Ovarian cancer is a severe malignant tumour of the female genital organs. Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) expression is correlated with the occurrence and progression of multiple cancers. Here, we assessed STEAP1 expression in ovarian cancer and explored the relationship between STEAP1 and ovarian cancer progression. We used immunohistochemistry and public databases to test STEAP1 expression in normal human ovarian tissues, benign ovarian tumours, and ovarian cancer. The expression of STEAP1 and epithelial-to-mesenchymal transition (EMT)-related genes was analysed using immunocytochemistry, quantitative reverse transcription polymerase chain reaction, and western blotting in ovarian cancer cell lines. Lentivirus was used to knockdown and overexpress STEAP1. Invasion, migration, growth, clonogenicity, and apoptosis were assessed using transwell assay, growth curve, plate clone formation assay, and flow cytometry. We used a tumour xenograft to verify the relationship between STEAP1 and in vivo ovarian cancer cell growth. Matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) activities were examined using Matrix metalloproteinase zymography assay. STEAP1 was highly expressed in the human ovarian cancer tissues and a highly invasive ovarian cancer cell line. Overexpression of STEAP1 was related to poor prognosis in ovarian cancer patients. Down-regulation of STEAP1 suppressed the invasion, migration, proliferation, clonogenicity, EMT progression in human ovarian cancer cells and xenograft tumour growth in vivo, but it enhanced apoptosis. In human ovarian cancer, the STEAP1 gene is highly expressed, and its function is correlated with human ovarian cancer cell metastasis and growth. STEAP1 may be a possible target for suppressing ovarian cancer metastasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allemani C et al (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977–1010. https://doi.org/10.1016/S0140-6736(14)62038-9
Barroca-Ferreira J et al (2018) Targeting STEAP1 protein in human cancer: current trends and future challenges. Curr Cancer Drug Targets 18:222–230. https://doi.org/10.2174/1568009617666170427103732
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Carrasquillo JA et al (2019) Imaging metastatic castration-resistant prostate cancer patients with89 Zr-DFO-MSTP2109A anti-STEAP1 antibody. J Nucl Med. https://doi.org/10.2967/jnumed.118.222844
Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564. https://doi.org/10.1126/science.1203543
Challita-Eid PM et al (2007) Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumour xenografts in vivo. Cancer Res 67:5798–5805. https://doi.org/10.1158/0008-5472.can-06-3849
Chen X, Wang R, Chen A, Wang Y, Wang Y, Zhou J, Cao R (2019) Inhibition of mouse RM-1 prostate cancer and B16F10 melanoma by the fusion protein of HSP65 and STEAP1 186-193. Biomed Pharmacother 111:1124–1131. https://doi.org/10.1016/j.biopha.2019.01.012
Cheung IY, Feng Y, Danis K, Shukla N, Meyers P, Ladanyi M, Cheung NKV (2007) Novel markers of subclinical disease for ewing family tumours from gene expression profiling. Clin Cancer Res 13:6978–6983. https://doi.org/10.1158/1078-0432.ccr-07-1417
De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97–110. https://doi.org/10.1038/nrc3447
Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20:69–84. https://doi.org/10.1038/s41580-018-0080-4
O Donoghue JA et al (2019) Pharmacokinetics and biodistribution of a [89 Zr]Zr-DFO-MSTP2109A anti-STEAP1 antibody in metastatic castration-resistant prostate cancer patients. Mol Pharm 16:3083–3090. https://doi.org/10.1021/acs.molpharmaceut.9b00326
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017). Lancet 390:1151–1210. https://doi.org/10.1016/S0140-6736(17)32152-9
Gomes IM, Rocha SM, Gaspar C, Alvelos MI, Santos CR, Socorro S, Maia CJ (2018) Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens. Med Oncol 35:40. https://doi.org/10.1007/s12032-018-1100-0
Goossens S, Vandamme N, Van Vlierberghe P, Berx G (2017) EMT transcription factors in cancer development re-evaluated: beyond EMT and MET. Biochim Biophys Acta Rev Cancer 1868:584–591. https://doi.org/10.1016/j.bbcan.2017.06.006
Grunewald TGP et al (2012a) STEAP1 is associated with the invasive and oxidative stress phenotype of ewing tumors. Mol Cancer Res 10:52–65. https://doi.org/10.1158/1541-7786.mcr-11-0524
Grunewald TGP et al (2012b) High STEAP1 expression is associated with improved outcome of Ewing’s sarcoma patients. Ann Oncol 23:2185–2190. https://doi.org/10.1093/annonc/mdr605
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hayashi S et al (2011) Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J Transl Med 9:191. https://doi.org/10.1186/1479-5876-9-191
Hubert RS et al (1999) STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96:14523–14528. https://doi.org/10.1073/pnas.96.25.14523
Ihlaseh-Catalano SM, Drigo SA, de Jesus CM, Domingues MA, Trindade Filho JC, de Camargo JL, Rogatto SR (2013) STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma. Histopathology 63:678–685. https://doi.org/10.1111/his.12226
Kurman RJ, Carcangiu LM, Herrington CS, Young RH (eds) (2014) WHO classification of tumours of female reproductive organs. IARC Press, Lyon
Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196. https://doi.org/10.1038/nrm3758
Lee CH et al (2016) The prognostic role of STEAP1 expression determined via immunohistochemistry staining in predicting prognosis of primary colorectal cancer: a survival analysis. Int J Mol Sci 17:e592. https://doi.org/10.3390/ijms17040592
Loret N, Denys H, Tummers P, Berx G (2019) The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers 11:838. https://doi.org/10.3390/cancers11060838
Maia CJB, Socorro S, Schmitt F, Santos CRA (2008) STEAP1 is over-expressed in breast cancer and down-regulated by 17β-estradiol in MCF-7 cells and in the rat mammary gland. Endocrine 34:108–116. https://doi.org/10.1007/s12020-008-9113-7
Nakamura H et al (2018) Six-transmembrane epithelial antigen of the prostate 1 protects against increased oxidative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer. Cancer Gene Ther 26:313–322. https://doi.org/10.1038/s41417-018-0056-8
Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, Sant M (2012) Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol 51:441–453. https://doi.org/10.3109/0284186x.2011.653437
Puisieux A, Brabletz T, Caramel J (2014) Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 16:488–494. https://doi.org/10.1038/ncb2976
Sun J, Ji G, Xie J, Jiao Z, Zhang H, Chen J (2019) Six-transmembrane epithelial antigen of the prostate 1 is associated with tumour invasion and migration in endometrial carcinomas. J Cell Biochem 120:11172–11189. https://doi.org/10.1002/jcb.28393
Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142. https://doi.org/10.1038/nrm1835
Vaughan S et al (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11:719–725. https://doi.org/10.1038/nrc3144
Wu YY, Jiang JN, Fang XD, Ji FJ (2018) STEAP1 regulates tumorigenesis and chemoresistance during peritoneal metastasis of gastric cancer. Front Physiol 9:1132. https://doi.org/10.3389/fphys.2018.01132
Xie J, Yang Y, Sun J, Jiao Z, Zhang H, Chen J (2019) STEAP1 inhibits breast cancer metastasis and is associated with epithelial–mesenchymal transition procession. Clinical Breast Cancer 19(1):e195–e207. https://doi.org/10.1016/j.clbc.2018.08.010
Yamamoto T et al (2013) Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumour growth via intercellular communication. Exp Cell Res 319:2617–2626. https://doi.org/10.1016/j.yexcr.2013.07.025
Zhuang X et al (2015) Identification of novel vascular targets in lung cancer. Br J Cancer 112:485–494. https://doi.org/10.1038/bjc.2014.626
Acknowledgements
Our study was funded by Nature Science Foundation of Shandong Province (ZR2017MH060) and Key R&D Plan of Shandong Province (2018GSF118049). These funds provided only financial support and were not involved in the study or manuscript writing.
Funding
This study was funded by the Nature Science Foundation of Shandong Province (ZR2017MH060) and Key R&D Plan of Shandong Province (2018GSF118049).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors in this study declare that they have no conflict of interests.
Ethical approval
This study was approved by the Medical Ethics Committee of Human and Animal Institution of Shandong University. All methods were performed in accordance with the relevant guidelines and regulations.
Informed consent
We obtained the written informed consents of the patients involved in the study. All mouse experimental procedures were performed in accordance with the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of the People’s Republic of China.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Jiao, Z., Huang, L., Sun, J. et al. Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition. Histochem Cell Biol 154, 215–230 (2020). https://doi.org/10.1007/s00418-020-01877-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00418-020-01877-7